-
Product Insights
NewNeuromuscular Disorders – Drugs In Development, 2024
Empower your strategies with our Neuromuscular Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Neuromuscular disorders are conditions that affect the function of the nerves and muscles in the body. They can cause muscle weakness, fatigue, pain, spasms, and other symptoms. Neuromuscular disorders can be inherited or acquired, and they can affect different parts of the neuromuscular system, such as the peripheral nerves, the skeletal muscles, or the neuromuscular junction. Some examples of neuromuscular disorders are...
-
Product Insights
NewMyasthenia Gravis – Drugs In Development, 2024
Empower your strategies with our Myasthenia Gravis – Drugs In Development, 2024 report and make more profitable business decisions. Myasthenia gravis is an autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia, and difficulty swallowing, chewing, and speaking. Treatment includes immunosuppressants, corticosteroids, and surgery. The Myasthenia Gravis drugs in development market research report provide comprehensive information on the therapeutics under development for Myasthenia Gravis,...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery. The Myasthenia Gravis - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...
-
Company Insights
Disruptor Profile: TravelPerk S.L.
The report provides information and insights into TravelPerk S.L.'s, including - - Overview of the company and its product offering - Detailed insight into its business model, company type and headquarter - Information on fundings - Biography of top management